Collegium Pharmaceutical (COLL) PT Lowered to $48 at Barclays

August 19, 2026 3:21 AM

Barclays analyst Glen Santangelo lowered the price target on Collegium Pharmaceutical (NASDAQ: COLL) to $48.00 (from $56.00) while maintaining a Overweight rating.

No results found